We investigated gender differences in individuals with opioid use disorder (OUD) receiving inpatient services and entering a randomized controlled trial comparing extended-release naltrexone to buprenorphine. Methods: Participants (N ¼ 570) provided demographic, substance use, and psychiatric information. Results: Women were significantly younger, more likely to identify as bisexual, live with a sexual partner, be financially dependent, and less likely employed. Women reported significantly greater psychiatric comorbidity and risk behaviors, shorter duration but similar age of onset of opioid use. Discussion/Conclusions: Findings underscore economic, psychiatric, and infection vulnerability among women with OUD. Scientific Significance: Interventions targeting these disparities should be explored, as women may face complicated treatment initiation, retention, and recovery. (Am J Addict 2018;27:465-470) 
INTRODUCTION
Over 2.5 million people have an opioid use disorder (OUD) in the US. 1 While there was a 265% increase in prescription opioid overdoses for men between 1999 and 2010, women had a 400% increase. 2 Currently, approximately 31 women die each day from opioid overdoses. 3 Gender differences arise when looking at profiles of men and women with OUD, where women report more issues with drug, medical, psychological, family/social, and employment problems, while men have more problems with legal and alcohol-related issues. 4 Treatment providers may lack awareness of such differences, or programs may lack infrastructure to support gender-related differences during treatment.
The purpose of this analysis is to investigate gender differences in demographic and clinical characteristics in a sample of individuals entering a national multi-site randomized controlled medication trial for OUD. This unique trial offers a critical opportunity to investigate gender differences among treatment seeking individuals with OUD using a recently collected, nationally diverse sample.
METHOD Participants
Data for this analysis were drawn from a 2-hour baseline assessment of a randomized controlled 24-week open-label comparative effectiveness trial of buprenorphine versus extended-release naltrexone (XR-naltrexone) for individuals with OUD. 5 Participants (N ¼ 570) were recruited directly from eight inpatient detoxification units across the US and randomly assigned to receive buprenorphine or XR-naltrexone. Willingness to accept either medication was a condition of enrollment. The baseline occurred prior to randomization and patients received $50 for completion. All participants completed informed consent procedures prior to baseline and all sites obtained local Institutional Review Board approval.
Measures
Data utilized for this report were generated by self-report. Variables (Table 1) included basic demographics, substance use, including cigarette smoking and opioid-specific variables (eg, money spent per day, age of onset, duration of use, withdrawal discomfort), treatment preference and history, current mental health and psychiatric history, general physical health, and drug and sex risk behaviors. 5 
Statistical Methods
Descriptive analyses were conducted for all outcomes of interest on the total randomized sample and stratified by gender. For categorical variables, data are presented as percentages and chi-square tests were used to test differences by gender (female vs male). For continuous variables, data are presented as means and standard deviations and t-tests were used to test differences by gender. Fisher's exact test (FET) was used for categorical variables with expected cell size less than 5 in more than 20% of cells. All hypothesis tests were performed two-sided, 5% level of significance. Given the exploratory nature of this analysis, corrections for multiple comparisons were not employed; however, results of p < .001 would be considered significant under multiple comparison constraints. Women reported fewer lifetime drug treatments (M ¼ 4.1) compared to men (M ¼ 5.7) (p ¼ .04), however, no differences were detected on whether the current episode was a first treatment episode, whether a previous treatment episode was successful, or preference for buprenorphine or XR-naltrexone. Of the sample, 39.5% reported being treated with buprenorphine in the past, 31.8% with methadone, and 4.6% with XRnaltrexone, with no differences by gender.
RESULTS

Sociodemographics
Mental Health
More women than men reported psychiatric history (79.3 vs 58.1%; p < .001), including anxiety/panic disorder (59.8 vs 38.9%; p < .001), bipolar disorder (20.1 vs 11.2%; p ¼ .01), and major depression (37.3 vs 28.9%; p ¼ .05). Women also were more likely to report a history of suicidal behavior (17.2 vs 10.0%; p ¼ .02), physical abuse (64.3 vs 30.7%; p < .001), and sexual abuse (53.3 vs 15.8%; p < .001), as well as report more days in the past month where their mental health was "not good" (M ¼ 13.8 vs M ¼ 11.0; p ¼ .01) compared to men. Scores on the Hamilton Rating Scale for Depression (HAM-D) were not significantly different by gender.
Physical Health
No significant differences were detected for presence of chronic health problems, chronic pain lasting more than 6 months, or days in the past 30 where physical health was "not good."
Sex and Drug Risk Behaviors
Significantly more women than men reported exchanging sex for drugs (26.2 vs 2.8%; p < .001) and sharing injection equipment (25.1 vs 15.2%; p ¼ .01). There was no difference by gender for moderate, considerable, or extreme concern about HIV transmission.
DISCUSSION
Similar to previous research, 6 results showed that women in our sample were younger, demonstrated greater economic vulnerability (more likely to be unemployed, despite similar education levels; dependent on someone else for their support; living with a sexual partner or with children alone; and living with someone also using illicit drugs), greater psychiatric comorbidity, and a greater prevalence of histories of physical and sexual abuse, compared to the men. Findings suggest that women's substance use may be more integrated with a sexual partner's use (more likely to live with a partner or live with someone with a drug problem, be dependent on someone else financially, or share injection equipment), which also replicates prior research 7 and may complicate treatment initiation, retention, and recovery. Interventions that address the significant prevalence of co-occurring psychiatric disorders, suicidal behaviors, and trauma histories among women with OUD is especially necessary given the rising rate of opioid deaths in women including suicides. Greater drug and sexual risk behaviors among women, including 25% of women reporting exchanging sex for drugs and sharing injection equipment, warrants increased emphasis on risk reduction interventions in addiction specialty programs as well as awareness of these risks throughout the healthcare system. Gender differences in HIV risk among treatment seeking women and men with substance use disorders vary depending on population and behavior, 9 but given the reach of the current opioid epidemic, results of this analysis are of particular concern. Women were also more likely to identify as bisexual-an identity associated with greater risk behaviors and substance use. 10 With almost 13% of women identifying as bisexual, results indicate the need for greater competencies and attention to sexual minority women's health needs.
8
Women in this sample initiated opioid use at the same age as men (21 years for both women and men), but women were younger overall, suggesting the need for treatment earlier in their disease progression. Other measures of drug use severity were also similar, including use of other drugs and alcohol and amount spent on opioids per day. Fewer treatment episodes for women may be a factor of their younger age, but barriers to women's access to OUD treatment should also be explored. Women and men reported similar preference for either buprenorphine or XR-naltrexone and there were similar rates of previous exposure to these medications. Although XRnaltrexone has been approved only since 2010, the extremely low rates of previous exposure suggest the need for greater access to all evidence-based medications, especially given that this study showed equivalent safety and effectiveness (once induction was complete) between the two medications. 5 High preference rates for both medications indicates that broadening treatment access can assist patients in receiving treatments consistent with their preferences and other clinical needs.
The current study is one of the largest randomized controlled trials testing the effectiveness of buprenorphine and XR-naltrexone and benefits from geographic diversity. Generalizability of these results is limited to treatment seeking men and women able to access inpatient care. Findings replicate prior gender differences in SUD research results while underscoring the economic vulnerability, psychiatric comorbidity, high risk for infection, and other complications of opioid use among women with OUDs, and specific risk among sexual minority women. Gender-specific interventions focused on these areas of disparity for women with OUD should be considered, including integration of OUD care with treatment for co-occurring psychiatric disorders and trauma, couples-based risk reduction interventions which address relational dynamics, and interventions that address the unique needs of sexual minority women.
